Home
Conditions
Neurocutaneous Syndromes

Clinical trial condition

Neurocutaneous Syndromes

Explore clinical trials studying Neurocutaneous Syndromes. Study availability and eligibility vary by location and protocol.

347 public trials 63 recruiting studies

Refine in advanced search Browse all conditions

Neurocutaneous Syndromes trial results

Recruiting

Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas

NCT04750928

Conditions: Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Heredodegenerative Disorders, Nervous System, +13 more
Locations: National Institutes of Health Clinical Center Bethesda, Maryland, United States

View Trial Details

Recruiting

Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative Study

NCT06880991

Conditions: Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Heredodegenerative Disorders, Nervous System, +16 more
Locations: National Institutes of Health Clinical Center Bethesda, Maryland, United States

View Trial Details

Recruiting

Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial

NCT05361811

Conditions: Abnormalities, Multiple, Cardiofaciocutaneous Syndrome, Cardiofaciocutaneous syndrome, +30 more
Locations: National Cancer Institute (NCI) Bethesda, Maryland, United States

View Trial Details

Recruiting

Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)

NCT06222203

Conditions: Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Fibrosarcoma, Genetic Diseases, Inborn, +22 more
Locations: National Institutes of Health Clinical Center Bethesda, Maryland, United States

View Trial Details

Recruiting

Study of Skin Tumors in Tuberous Sclerosis

NCT00001975

Conditions: Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, +12 more
Locations: National Institutes of Health Clinical Center Bethesda, Maryland, United States

View Trial Details

Recruiting

Study of the Disease Process of Lymphangioleiomyomatosis

NCT00001465

Conditions: Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, +28 more
Locations: National Institutes of Health Clinical Center Bethesda, Maryland, United States

View Trial Details

Recruiting

Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)

NCT07287202

Conditions: Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Craniofacial Abnormalities, +19 more
Locations: Austin Hospital Heidelberg, Victoria, Australia

The Alfred Melbourne, Victoria, Australia

View Trial Details

Recruiting

Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

NCT07405164

Conditions: Abnormalities, Multiple, Angiomatosis, Cardiovascular Diseases, +11 more
Locations: Beth Israel Deaconess Medical Center ( Site 0107) Boston, Massachusetts, United States

Dana-Farber Cancer Institute ( Site 0105) Boston, Massachusetts, United States

Karmanos Cancer Center ( Site 0108) Detroit, Michigan, United States

Hospital of the University of Pennsylvania Perelman Center for Advanced Medicine ( Site 0100) Philadelphia, Pennsylvania, United States

View all 49 locations

View Trial Details

Recruiting

Natural History Study of Patients With Neurofibromatosis Type 2

NCT00598351

Conditions: Central Nervous System Diseases, Central Nervous System Neoplasms, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +38 more
Locations: National Institutes of Health Clinical Center Bethesda, Maryland, United States

View Trial Details

Recruiting

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

NCT04924075

Conditions: Abnormalities, Multiple, Adenoma, Adenoma, Islet Cell, +31 more
Locations: Cedars-Sinai Medical Center ( Site 0110) Los Angeles, California, United States

Northwestern University - Robert H. Lurie Comprehensive Cancer Center ( Site 0130) Chicago, Illinois, United States

Northwestern Medicine Cancer Center - Warrenville ( Site 0134) Warrenville, Illinois, United States

University of Iowa ( Site 0104) Iowa City, Iowa, United States

View all 84 locations

View Trial Details

Neurocutaneous Syndromes

Neurocutaneous Syndromes trial results

Related conditions